Skip to main content

Table 1 Clinical parameters of patients

From: Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer

  Control PDAC CP
   non-cachexia cachexia p non-cachexia cachexia p
N 13 23 13   19 6 ns
Female 6 (46%) 11 (48%) 6 (46%) ns 10 (53%) 2 (33%)
Male 7 (54%) 12 (52%) 7 (54%)   9 (47%) 4 (67%
Age, years 63 (19–78) 68 (41–88) 61 (52–77) ns 50 (36–77) 49 (44–73) ns
UICC stage nr I 2 (9%)   ns nr nr  
II 16 (70%) II 5 (38%)
III 2 (9%) III 1 (8%)
IV 3 (12%) IV 7 (54%)
ASA I 18% 7% 9% ns 23%   ns
II 73% 64% 64%   46% 67%
III 9% 29% 27%   31% 33%
Jaundice 0 (0%) 5 (22%) 5 (38%) ns 0 (0%) 1 (17%) ns
Weight loss, kg 0.0 (0) 2 (0–8) 12,5 (6–34) < 0.001# 0 (0–6) 12,5 (8–40) < 0.001##
Weight loss, % 0.0 (0) 3.0 (0–9.2) 14.0 (10.0–26.6) < 0.001# 0 (0–9.1) 15.7 (11.1–28.6) < 0.001##
Perirenal fat, mm 15.2 (6.7–32.5) 11.0 (2.0–39.0) 11.6 (4.0–26.2) ns 6 (2.5–22.4) 7.0 (5.2–19.1) 0.013§§
M. erector spinae, mm 36.2 (28.9–39.8) 30.3 (18.7–39.1) 31.1 (26.0–41.4) ns 32.1 (24.3–47.4) 40.5 (36.7–45.1) 0.019##
M. psoas, mm 37.0 (30.6–53.8) 38.0 (25.1–43.5) 32.8 (25.0–39.5) ns 37.9 (20.7–51.2) 28.8 (22.6–35.7) 0.030°°
0.039##
M. psoas area, mm2 1044,2 (876,2–1997,0) 1022,1 (608,7–1371,8) 702,1 (527,3–1075,2) 0.035° 943,5 (345,7–1971,5) 714,4 (565,9–931,3)  
0.031#
Subcutaneous fat medial, mm 17.8 (6.7–62.6) 14.0 (3.0–60.6) 20.7 (1.1–50.4) ns 8.2 (0.6–62.3) 6.3 (2.5–31.2)  
Subcutaneous fat lateral, mm 45.0 (29.1–92.0) 37.1 (14.9–77.5) 38.3 (7.7–72.4) ns 33.5 (4.3–94.5) 34.6 (22.3–45.3)  
  1. Values are demonstrated as median (minimum-maximum)
  2. ns not significant; nr not relevant
  3. ° PDAC with cachexia versus control; # PDAC without cachexia versus PDAC with cachexia
  4. §§ CP without cachexia versus control; °° CP with cachexia versus control; ## CP without cachexia versus CP with cachexia